SSM - Mental Health
June 16, 2026
Caroline Krauser, Eduardo Jardim Simões, Chester Schmaltz et al.
Depressive and anxiety symptoms are one of the leading causes of years lived with disability worldwide. Mindfulness-based interventions (MBIs) have been shown to be one of the proven treatments for improving mild and moderate cases of depression and anxiety. However, there is still a gap regarding the feasibility and effectiveness of MBIs in the real world, especially in low- and middle-income...
European Psychiatry
June 16, 2026
A.H. Young, Lucie Bartova, N. Cardoner et al.
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Neuropsychopharmacology
June 16, 2026
Nadia S. Hejazi, Mina Kheirkhah, Brady A. Riedner et al.
Slow-wave activity (SWA), a key indicator of sleep homeostasis, is often diminished in individuals with treatment-resistant depression (TRD). Ketamine, a rapid-acting antidepressant, increases SWA during the first period of non-rapid eye movement (NREM1) sleep. However, research into how ketamine affects sleep and its connection to treatment outcomes in TRD has been limited by small sample...
Psychiatry Research
June 16, 2026
Filippo Mazzoni, Fabiola Raffone, Arianna De Ciechi et al.
Borderline personality disorder (BPD) often occurs alongside treatment-resistant depression (TRD), but the impact of BPD on real-world outcomes with intranasal esketamine is unclear. Consecutive TRD outpatients initiating intranasal esketamine treatment at four Italian centres between 1 September 2024 and 30 September 2025 were enrolled in the study (n = 90): 45 with comorbid BPD and 45 without...
bioRxiv (Cold Spring Harbor Laboratory)
June 16, 2026
Paulina Clara Dagnino, Irene Acero-Pousa, Gorka Zamora-López et al.
1 citation
preprint
Abstract In recent decades, the psychedelic psilocybin has been studied as a potential treatment for major depressive disorder (MDD), offering an alternative to traditional antidepressants. However, the brain changes underlying the clinical effects of different interventions remain unclear. Here, we investigated the effects of psilocybin and a conventional antidepressant, escitalopram, from the...
Psychedelic Medicine
June 16, 2026
Max Wolff, Samuli Kangaslampi, Richard J. Zeifman et al.
This commentary critically examines the interpretation and analytic choices in Goodwin and colleagues’ recent analysis of therapeutic alliance in psilocybin treatment for treatment-resistant depression. While the authors conclude that alliance did not meaningfully contribute to treatment efficacy, we argue that this interpretation is not supported by the reported results, which are, in...
International Journal of Innovative Technologies in Social Science
June 15, 2026
Olga Szeidl, Joanna Mikołajczyk, Artur Hawajski et al.
Background: Depression is a multifactorial disorder involving neurotransmitter dysregulation, HPA axis hyperactivity, neuroinflammation, and impaired neuroplasticity. While combination psychotherapy and pharmacotherapy remains first-line, ~30% of patients develop TRD. In the last few years ketamine has emerged as a rapid-acting therapeutic option for treatment-resistant cases. Aim: To review...
Research Square
June 15, 2026
Yuping Liu, Bingtao Zhou, Fengxu Qiang et al.
preprint
Abstract Background Mindfulness is reliably associated with lower anxiety and depression, yet the longitudinal within-person dynamics and potential differences between these two forms of emotional distress remain largely unknown. Methods A total of 1,138 participants completed five waves of self-report assessments at two-week intervals. Mindfulness, anxiety, and depression were measured at each...
Acta Psychologica
June 15, 2026
Vera Scheepbouwer, Imke Hanssen, Rhoda Schuling et al.
Objectives: Compassion-based interventions, like Mindfulness-Based Compassionate Living (MBCL), are increasingly recognized as treatments for depression. This study explores the impact of MBCL on self-schemas. Methods: As part of an RCT on MBCL for depression, self-description interviews of approximately 3 min in duration were conducted with 24 patients before and after MBCL and were analyzed...
Ugeskrift for Læger
June 15, 2026
Mikkel Marquardsen
This review presents the status of Mindfulness-Based Cognitive Therapy (MBCT) in the treatment of active depression. The theoretical underpinnings of MBCT are outlined, along with potential mediating and moderating factors influencing treatment outcomes. Several randomised controlled trials indicate that MBCT demonstrates efficacy comparable to other evidence-based interventions. However, MBCT...